Skip to main content
. Author manuscript; available in PMC: 2015 Sep 29.
Published in final edited form as: Cancer Res. 2006 Aug 1;66(15):7639–7646. doi: 10.1158/0008-5472.CAN-06-0419

Figure 3.

Figure 3

Rapamycin inhibits mTOR activity in vivo and promotes apoptosis in response to chemotherapy. A, lysates prepared from Eμ-myc/PTEN+/− tumors either left untreated (U) or 6 hours following in vivo treatment with doxorubicin (D), rapamycin (R), or doxorubicin and rapamycin (D + R), and probed for PTEN, phosphorylated and total Akt, and ribosomal S6 protein, and α-tubulin. B, representative micrographs of Eμ-myc/PTEN+/− tumors untreated or 18 hours after treatment with doxorubicin, rapamycin, or doxorubicin + rapamycin and stained with H&E or immunohistochemical probing detecting the phosphorylated forms of Akt and ribosomal S6 protein or TUNEL.